Business Context and Reporting Period
Company: Aspen Aerogels, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2019
Event: Entry into a material definitive agreement (Addendum to Supply Agreement with BASF Polyurethanes GmbH).
Key Financial Metrics and Obligations
- Prepayment Received: $5 million (Second Tranche Prepayment from BASF).
- Payment Deadline: No later than January 31, 2019.
- Repayment Mechanism: Up to 50% of amounts invoiced for the "Developed Product" sold to BASF will be credited against the prepayment balance.
- Alternative Repayment (Post-2022): If a balance remains after December 31, 2022, BASF may require a credit of 24.7% of payments for Spaceloft® A2 product or direct cash repayment.
- Voluntary Repayment: The Company may repay the prepayment in whole or in part at any time.
Material Changes and Covenant Waivers
The receipt of the $5 million prepayment is a condition precedent for a waiver of the Company's failure to comply with the Adjusted Quick Ratio financial covenant under its Loan Agreement with Silicon Valley Bank (SVB) for the periods ending August 31, 2018, and November 30, 2018.
Conditions for Waiver:
- Receipt of the Second Tranche Prepayment by January 31, 2019.
- Submission of a Compliance Certificate to SVB indicating no event of default has occurred as of January 31, 2019.
Outlook, Risks, and Contingencies
Product Expansion: The Addendum includes the "Developed Product" as an additional item to be supplied to BASF under the existing Supply Agreement.
Contingencies: The waiver of the financial covenant is contingent upon the timely receipt of funds and the submission of a compliance certificate. The filing does not provide specific revenue, profit, or cash flow figures for the period, nor does it detail the specific nature of the "Developed Product."
Investor Verification Checklist
- Confirm the actual receipt of the $5 million prepayment by January 31, 2019.
- Verify the submission of the Compliance Certificate to Silicon Valley Bank and the formal waiver of the Adjusted Quick Ratio covenant.
- Review the definition and commercial viability of the "Developed Product" to assess future revenue potential.
- Monitor the Company's ability to meet future financial covenants under the Loan Agreement.